2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

4:30PM-6:00PM: Abstract Number: 2835

A Burden of Missense Genetic Variants in Urate Secretory Genes Is Associated with Inadequate Response to Allopurinol in People with Gout

5T112: Metabolic & Crystal Arthropathies II: Genetics & Physiology (2834–2839)

4:30PM-6:00PM: Abstract Number: 2841

A Double-Blind, Placebo-Controlled, Phase 2 Trial of a Novel Toll-Like Receptor 7/8/9 Antagonist (IMO-8400) in Dermatomyositis

5T113: Muscle Biology, Myositis & Myopathies II (2840–2845)

4:30PM-6:00PM: Abstract Number: 2812

A New Role for Selectins in Systemic Lupus Erythematosus

5T115: SLE – Etiology & Pathogenesis I: Signaling Pathways (2810–2815)

4:30PM-6:00PM: Abstract Number: 2807

Activation of the STING Pathway Is a Shared Feature of Salivary Gland and Lung Inflammation in Sjogren’s Syndrome

5T110: Innate Immunity (2804–2809)

4:30PM-6:00PM: Abstract Number: 2816

An Expanded Granzyme K+ CD8 T Cell Population Induces Inflammatory Responses in Rheumatoid Arthritis Synovium

5T117: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2816–2821)

4:30PM-6:00PM: Abstract Number: 2824

Antibiotic Use and the Development of Rheumatoid Arthritis (RA) and Risk of RA Flares: Case-Control and Self-Controlled Case Series Studies in Two National Electronic Patient Databases (SIDIAP and CPRD)

5T109: Epidemiology & Public Health III: RA (2822–2827)

4:30PM-6:00PM: Abstract Number: 2834

Assessing the Risk of Gout with Sodium Glucose Co-Transporter-2 Inhibitors: A Population-Based Cohort Study

5T112: Metabolic & Crystal Arthropathies II: Genetics & Physiology (2834–2839)

4:30PM-6:00PM: Abstract Number: 2839

Association of a Gout Polygenic Risk Score with Disease Severity Phenotypes Amongst Caucasian Gout Patients in Three Independent Cohorts

5T112: Metabolic & Crystal Arthropathies II: Genetics & Physiology (2834–2839)

4:30PM-6:00PM: Abstract Number: 2837

Asymptomatic Monosodium Urate Crystal Deposition Associates with Increased Expression of Pro-Inflammatory Genes

5T112: Metabolic & Crystal Arthropathies II: Genetics & Physiology (2834–2839)

4:30PM-6:00PM: Abstract Number: 2820

Calcium/ Calmodulin – Dependent Protein Kinase IV Associates with Phosphofructokinase to Promote Glycolysis and Limit IL-2 Production

5T117: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2816–2821)

4:30PM-6:00PM: Abstract Number: 2855

Clinically Relevant Patient Clusters Identified by Machine Learning Tools in a Large Database from the Secukinumab Psoriatic Arthritis Clinical Development Program

5T116: Spondyloarthritis Including Psoriatic Arthritis – Clinical VI: Psoriatic Arthritis Clinical Studies (2852–2857)

4:30PM-6:00PM: Abstract Number: 2821

Clonal Expansion of a Specific Subset of Cytotoxic CD4+T Cells and Tissue Apoptosis in Patients with IgG4-related Disease

5T117: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2816–2821)

4:30PM-6:00PM: Abstract Number: 2831

Cracks in Your Referral Process? Find Your Sustainable Solution Here

5T111: Measures of Healthcare Quality II: Quality Improvement in Rheumatology – Still Getting Better (2828–2833)

4:30PM-6:00PM: Abstract Number: 2857

Decision Tree Analysis to Identify Inflammatory Arthritis Patient Subgroups with Different Levels of Treatment Persistence with First-Line Subcutaneous TNF-alpha Inhibitors

5T116: Spondyloarthritis Including Psoriatic Arthritis – Clinical VI: Psoriatic Arthritis Clinical Studies (2852–2857)

4:30PM-6:00PM: Abstract Number: 2854

Delay Between the Onset of Psoriasis and Arthritis in PsA Patients from the PsART International Cohort

5T116: Spondyloarthritis Including Psoriatic Arthritis – Clinical VI: Psoriatic Arthritis Clinical Studies (2852–2857)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].